Date: 2015-09-27
Type of information: Licensing agreement
Compound: JAK inhibitors
Company: Rigel Pharmaceuticals (USA - CA) Aclaris Therapeutics (USA - PA)
Therapeutic area: Autoimmune diseases - Dermatological diseases
Type agreement: licensing development commercialisation
Action mechanism: janus kinase inhibitor
Disease: alopecia areata
Details: * On September 9, 2015, Rigel Pharmaceuticals announced that Aclaris Therapeutics International Limited (ATIL), a wholly owned subsidiary of Aclaris Therapeutics, Inc., and Rigel have entered into an exclusive, worldwide license agreement for the development and commercialization of specified Rigel JAK inhibitors for the treatment of alopecia areata and other dermatological conditions. Under the license agreement, ATIL will assume responsibility for the continued development of specified Rigel JAK inhibitor compounds for the treatment of alopecia areata and other dermatological conditions.
Financial terms: Rigel will receive an upfront payment of $8 million, and will be eligible to receive various milestone payments of up to $90 million based on global development and multiple indications, as well as tiered royalties on any future sales of these compounds.
Latest news:
